Audrey Claperon

Croissy-sur-seine, 78290, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Discovery of S64315, a Potent and Selective Mcl-1 Inhibitor.

Discovery of S64315, a Potent and Selective Mcl-1 Inhibitor.

Journal: Journal of medicinal chemistry
Published: November 04, 2020

Structure-Guided Discovery of a Selective Mcl-1 Inhibitor with Cellular Activity.

Structure-Guided Discovery of a Selective Mcl-1 Inhibitor with Cellular Activity.

Journal: Journal of medicinal chemistry
Published: July 25, 2019

Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.

Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.

Journal: Leukemia
Published: June 05, 2018

The IGF2/IR/IGF1R Pathway in Tumor Cells and Myofibroblasts Mediates Resistance to EGFR Inhibition in Cholangiocarcinoma.

The IGF2/IR/IGF1R Pathway in Tumor Cells and Myofibroblasts Mediates Resistance to EGFR Inhibition in Cholangiocarcinoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 14, 2017

S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth.

S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth.

Journal: Oncotarget
Published: September 12, 2017

Role of the PDZ-scaffold protein NHERF1/EBP50 in cancer biology: from signaling regulation to clinical relevance.

Role of the PDZ-scaffold protein NHERF1/EBP50 in cancer biology: from signaling regulation to clinical relevance.

Journal: Oncogene
Published: September 16, 2016

Epithelial-mesenchymal transition in cholangiocarcinoma: From clinical evidence to regulatory networks.

Epithelial-mesenchymal transition in cholangiocarcinoma: From clinical evidence to regulatory networks.

Journal: Journal of hepatology
Published: May 23, 2016

Mitogen-activated protein kinase-activated protein kinase 2 mediates resistance to hydrogen peroxide-induced oxidative stress in human hepatobiliary cancer cells.

Mitogen-activated protein kinase-activated protein kinase 2 mediates resistance to hydrogen peroxide-induced oxidative stress in human hepatobiliary cancer cells.

Journal: Free radical biology & medicine
Published: May 15, 2015

Loss of ezrin in human intrahepatic cholangiocarcinoma is associated with ectopic expression of E-cadherin.

Loss of ezrin in human intrahepatic cholangiocarcinoma is associated with ectopic expression of E-cadherin.

Journal: Histopathology
Published: April 17, 2015

EGF/EGFR axis contributes to the progression of cholangiocarcinoma through the induction of an epithelial-mesenchymal transition.

EGF/EGFR axis contributes to the progression of cholangiocarcinoma through the induction of an epithelial-mesenchymal transition.

Journal: Journal of hepatology
Published: October 15, 2013

Mechanical induction of the tumorigenic β-catenin pathway by tumour growth pressure.

Mechanical induction of the tumorigenic β-catenin pathway by tumour growth pressure.

Journal: Nature
Published: August 01, 2013

Mitogenic insulin receptor-A is overexpressed in human hepatocellular carcinoma due to EGFR-mediated dysregulation of RNA splicing factors.

Mitogenic insulin receptor-A is overexpressed in human hepatocellular carcinoma due to EGFR-mediated dysregulation of RNA splicing factors.

Journal: Cancer research
Published: May 02, 2013
Showing 1-12 of 15

Last Updated: 09/26/2026